Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

27.95B

Market cap27.95B

Price-Earnings ratio

21.44

Price-Earnings ratio21.44

Dividend yield

—

Dividend yield—

Average volume

895.47K

Average volume895.47K

High today

$192.76

High today$192.76

Low today

$185.00

Low today$185.00

Open price

$187.54

Open price$187.54

Volume

861.37K

Volume861.37K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$110.04

52 Week low$110.04

Stock Snapshot

Biogen(BIIB) stock is priced at $190.48, giving the company a market capitalization of 27.95B. It carries a P/E multiple of 21.44.

On 2026-03-12, Biogen(BIIB) stock moved within a range of $185.00 to $192.76. With shares now at $190.48, the stock is trading +3.0% above its intraday low and -1.2% below the session's peak.

Trading activity shows a volume of 861.37K, compared to an average daily volume of 895.47K.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

BIIB News

TipRanks 10h

Biogen Announces Upcoming Departure of Chief Legal Officer

Biogen ( (BIIB) ) has issued an update. On March 11, 2026, Biogen Inc. announced that its Chief Legal Officer, Susan H. Alexander, will leave the company at th...

Simply Wall St 4d

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

Biogen (NasdaqGS:BIIB) and Stoke Therapeutics reported promising clinical results for zorevunersen in Dravet syndrome, with data highlighting durable seizure re...

Analyst ratings

56%

of 36 ratings

Buy

41.7%

Hold

55.6%

Sell

2.8%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.